Arthur T. Sands - 20 Jan 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
President, CEO, Director
Signature
/s/ Christine Ring, as Attorney-in-Fact for Arthur T. Sands
Issuer symbol
NRIX
Transactions as of
20 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 15:25:53 UTC
Next filing
10 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +300,000 $0.000000 300,000 20 Jan 2022 Common Stock 300,000 $18.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/48 of the total shares monthly beginning February 20, 2022 until the option is fully vested on January 20, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.